http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to results generated by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, and presented today at the American Association for Cancer Research (AACR) Annual Meeting 2013. http://medicalxpress.com/news/2013-04-clinical-trial-results-bind-aacr.html Cancer Tue, 09 Apr 2013 13:35:53 EST news284733345 Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic cancer and oral rigosertib is being studied in a pair of Phase II trials in lower-risk transfusion dependent MDS patients. The drug candidate is being developed by Onconova Therapeutics, Inc., of Pennington, NJ. http://medicalxpress.com/news/2013-04-rigosertib-phase-results-disease-focused.html Cancer Tue, 09 Apr 2013 10:34:46 EST news284722475 A new class of influenza drug has been shown effective against drug-resistant strains of the flu virus, according to a study led by University of British Columbia researchers. http://medicalxpress.com/news/2013-02-flu-drug-virus-tracks.html Medical research Thu, 21 Feb 2013 14:00:11 EST news280676007 An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options. http://medicalxpress.com/news/2013-02-multi-resistant-germs.html Diseases, Conditions, Syndromes Wed, 13 Feb 2013 09:51:22 EST news279971456 A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced. Scientists from the NIH's National Center for Advancing Translational Sciences (NCATS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will conduct the clinical trial at the NIH Clinical Center. Reaching this trial stage required collaboration among government, industry, patient advocacy groups and academic researchers. http://medicalxpress.com/news/2013-01-nih-clinical-trial-treatment-rare.html Diseases, Conditions, Syndromes Wed, 23 Jan 2013 10:41:01 EST news278160027 A collaboration between scientists in Munich, Germany and Bloomington, USA may have overcome one of the major challenges drug makers have struggled with for years: Delivering powerful nuclear hormones to specific tissues, while keeping them away from others. http://medicalxpress.com/news/2012-11-diabetes-turbo-charged-gut-hormones.html Medical research Tue, 13 Nov 2012 11:27:54 EST news272028400 Washington State University researchers have developed a new drug candidate that dramatically improves the cognitive function of rats with Alzheimer's-like mental impairment. http://medicalxpress.com/news/2012-10-prospective-alzheimer-drug-brain-cell.html Alzheimer's disease & dementia Thu, 11 Oct 2012 04:04:39 EST news269147063 CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease. http://medicalxpress.com/news/2012-09-drug-candidate-diabetes-breakthrough.html Diabetes Wed, 26 Sep 2012 17:46:56 EST news267900403 (Medical Xpress)—A New Zealand-designed compound that shows promise against treatment-resistance tuberculosis (TB) has been selected as a drug candidate by international non-profit drug developer the Global Alliance for TB Drug Development (TB Alliance). http://medicalxpress.com/news/2012-09-compound-drug-candidate-tuberculosis.html Diseases, Conditions, Syndromes Mon, 17 Sep 2012 09:40:02 EST news267092533 A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine. A team of scientists working in Switzerland has shown how pyridomycin, a natural antibiotic produced by the bacterium Dactylosporangium fulvum, works. This promising drug candidate is active against many of the drug-resistant types of the tuberculosis bacterium that no longer respond to treatment with the front-line drug isoniazid. http://medicalxpress.com/news/2012-09-scientists-reveal-natural-antibiotic-tuberculosis.html Diseases, Conditions, Syndromes Mon, 17 Sep 2012 09:30:13 EST news267093003 Researchers from Munich and Naples have shown that minimal modification of a synthetic peptide with anti-HIV activity results in a new compound with more than two orders of magnitude higher binding affinity to the chemokine receptor CXCR4 and greatly improved anti-HIV activity. This could be a step toward the design of new, more effective drugs against AIDS, inflammatory diseases, and some forms of cancer. http://medicalxpress.com/news/2012-08-potential-drug-molecule-anti-hiv.html HIV & AIDS Thu, 09 Aug 2012 11:30:48 EST news263730642 (Medical Xpress) -- Research from Karolinska Institutet has identified a monoamine stabiliser as a potential new drug for the treatment of alcohol dependence. Tested on rats, whose reward system is gradually blunted by long-term alcohol abuse, the compound OSU6162 balances dopamine levels in the brain. This serves to reduce the craving for more alcohol to maintain normal feelings of wellbeing while removing the pleasure from drinking. http://medicalxpress.com/news/2012-07-potential-drug-alcohol.html Addiction Fri, 27 Jul 2012 04:55:19 EST news262583710 A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients. http://medicalxpress.com/news/2012-07-trial-major-milestone-tb-drugs.html Diseases, Conditions, Syndromes Mon, 23 Jul 2012 16:41:53 EST news262280507 A drug candidate that is nearing clinical trials against a Latin American parasite is showing additional promise as a cure for hookworm, one of the most widespread and insidious parasites afflicting developing nations, according to a collaborative study at UCSF and Yale University. http://medicalxpress.com/news/2012-07-drug-prospect-hookworm-infections.html Diseases, Conditions, Syndromes Tue, 03 Jul 2012 17:00:07 EST news260552452 (Medical Xpress) -- Researchers at the University of California, Davis, have discovered a class of natural compounds found within the body that may someday lead to pain relief for millions of diabetics and others suffering from chronic pain. http://medicalxpress.com/news/2012-06-discovery-combat-chronic-pain-diabetics.html Diabetes Tue, 26 Jun 2012 08:11:44 EST news259917082 BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting. BIND presented data from the ongoing Phase 1 clinical study of BIND-014, its targeted docetaxel Accurin, in patients with solid tumors that strongly translated from preclinical data, demonstrated safety and tolerability, and showed evidence of anti-tumor activity with six of 17 patients with advanced or metastatic solid tumor cancers. The preliminary Phase 1 data demonstrated partial response or stable disease in this heavily pretreated patient population with durable responses of up to six months in some cases. In addition, BIND-014 demonstrated evidence of anti-tumor activity in tumors for which conventional docetaxel is known to have minimal activity. http://medicalxpress.com/news/2012-04-late-breaker-clinical-aacr-bind-antitumor.html Cancer Wed, 04 Apr 2012 10:16:52 EST news252753402 A drug candidate that has shown promise for neutralizing dangerous bacteria also prevents the parasite that causes malaria from growing, new research by a Yale University team headed by Nobel laureate Sidney Altman shows. http://medicalxpress.com/news/2012-04-compound-halts-growth-malaria-parasite.html Medical research Mon, 02 Apr 2012 15:00:17 EST news252585368 A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer's disease, based on the findings of a study published today in PLoS One. http://medicalxpress.com/news/2011-12-alzheimer-drug-candidate-disease.html Medications Wed, 14 Dec 2011 16:11:35 EST news243101466 MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs. http://medicalxpress.com/news/2011-09-powerful-diff-treatment.html Diseases, Conditions, Syndromes Mon, 19 Sep 2011 15:49:59 EST news235666182 Scientists at the Gladstone Institutes have identified a drug candidate that diminishes the effects of both Alzheimer's disease and Huntington's disease in animal models, offering new hope for patients who currently lack any medications to halt the progression of these two debilitating illnesses. http://medicalxpress.com/news/2011-06-scientists-drug-candidate-alzheimer-huntington.html Medical research Thu, 02 Jun 2011 13:43:10 EST news226240874